Antonio Lax
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Lax has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Domingo Andrés Pascual Figal
Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
33 shared publications Fernando Soler
Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla and University of Murcia, Ctra. Madrid-Cartagena S/N, Murcia, Spain
9 shared publicationsJames L. Januzzi
Division of Cardiology, Massachusetts General Hospital, Baim Institute for Clinical Research, Boston (J.L.J.).
6 shared publicationsMaria Josefa Fernandez del Palacio
Department of Animal Medicine and Surgery. University of Murcia
6 shared publications- Antoni Bayes-Genis
Heart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV , Badalona
5 shared publications Mari C. Asensio-López
Biomedical Research Institute Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain
5 shared publications
Latest Publications
- 2 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (865)
MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and ultimately death. Therapeutic options targeting the underlying mechanisms of the disease are urgently needed. MicroRNAs (miRs) have emerged as critical regulators of cardiovascular homeostasis and disease. Here, we identified microRNA-224-5p (miR-224) as a regulator of pulmonary vascular remodeling and delineate its mechanism of action in PAH. miR-224 expression was increased in the lungs of patients with PAH and across multiple experimental models of pulmonary hypertension, including mouse, rat, and pig models, as well as in pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with PAH. In vitro, miR-224 overexpression was sufficient to induce PASMC proliferation. In vivo, adeno-associated virus 1 (AAV1)–mediated overexpression of miR-224 exacerbated PAH in mice, whereas intratracheal delivery of aerosolized AAV1–ToughDecoy–miR-224 or a chemically modified antisense oligonucleotide targeting miR-224 (LNA-224) attenuated disease severity in Sugen/Hypoxia (Su/Hx) and monocrotaline models in both mice and rats. Moreover, SMC-specific inhibition of miR-224 via an AAV1 vector expressing ToughDecoy–miR-224 reversed pulmonary vascular remodeling and improved right ventricular function in the Su/Hx mouse model. Mechanistically, miR-224 targeted multiple components of the bone morphogenetic protein (BMP)/transforming growth factor–β (TGFβ) signaling pathway, leading to suppressed BMP/SMAD signaling and enhanced TGFβ-associated responses. Inhibition of miR-224 restored the balance between growth-inhibitory BMP signaling and growth-promoting TGFβ signaling in PASMCs. Collectively, these findings identify miR-224 as a regulator of pulmonary vascular remodeling and highlight miR-224 inhibition as a promising therapeutic strategy for PAH.
- 2 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (865)
MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and ultimately death. Therapeutic options targeting the underlying mechanisms of the disease are urgently needed. MicroRNAs (miRs) have emerged as critical regulators of cardiovascular homeostasis and disease. Here, we identified microRNA-224-5p (miR-224) as a regulator of pulmonary vascular remodeling and delineate its mechanism of action in PAH. miR-224 expression was increased in the lungs of patients with PAH and across multiple experimental models of pulmonary hypertension, including mouse, rat, and pig models, as well as in pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with PAH. In vitro, miR-224 overexpression was sufficient to induce PASMC proliferation. In vivo, adeno-associated virus 1 (AAV1)–mediated overexpression of miR-224 exacerbated PAH in mice, whereas intratracheal delivery of aerosolized AAV1–ToughDecoy–miR-224 or a chemically modified antisense oligonucleotide targeting miR-224 (LNA-224) attenuated disease severity in Sugen/Hypoxia (Su/Hx) and monocrotaline models in both mice and rats. Moreover, SMC-specific inhibition of miR-224 via an AAV1 vector expressing ToughDecoy–miR-224 reversed pulmonary vascular remodeling and improved right ventricular function in the Su/Hx mouse model. Mechanistically, miR-224 targeted multiple components of the bone morphogenetic protein (BMP)/transforming growth factor–β (TGFβ) signaling pathway, leading to suppressed BMP/SMAD signaling and enhanced TGFβ-associated responses. Inhibition of miR-224 restored the balance between growth-inhibitory BMP signaling and growth-promoting TGFβ signaling in PASMCs. Collectively, these findings identify miR-224 as a regulator of pulmonary vascular remodeling and highlight miR-224 inhibition as a promising therapeutic strategy for PAH.
- Open Access
- 4 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Correction: AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
- 4 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Open AccessCorrection: AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
- Open Access
- 14 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10002
miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology and cardiovascular disease. miR-106b-5p, a member of the miR-106b-25 cluster, has been widely studied for its oncogenic activity in various malignancies. However, its role as a direct molecular driver of anthracycline-induced cardiotoxicity has only recently been uncovered. This finding highlights new therapeutic possibilities at the intersection of oncology and cardiovascular medicine. This review outlines the dual role of miR-106b-5p as a key modulator in both tumor progression and chemotherapy-induced cardiac dysfunction. miR-106b-5p is upregulated in numerous cancers—including breast, prostate, lung, gastric, colorectal, hepatocellular, and esophageal—and promotes tumorigenesis via suppression of tumor suppressors such as PTEN, BTG3, p21, and SMAD7, leading to activation of oncogenic pathways like PI3K/AKT and TGF-β. Importantly, we present the first evidence that miR-106b-5p is significantly upregulated in the myocardium in response to doxorubicin treatment, where it drives left ventricular dysfunction by targeting PR55α, a key regulator of PP2A activity. This pathway results in cytoplasmic HDAC4 accumulation, aberrant activation of the YY1 transcription factor, and upregulation of sST2, a biomarker linked to adverse cardiac remodeling and poor prognosis. In response, we developed AM106, a novel locked nucleic acid antagomir that silences miR-106 b-5p. Preclinical studies demonstrate that AM106 restores PR55α/PP2A activity, reduces sST2 expression, and prevents structural and functional cardiac damage without compromising anti-tumor efficacy. In parallel, artificial intelligence (AI) tools could be leveraged in the future—based on established AI applications in miRNA cancer research—to accelerate the identification of miR-106b-5p-related biomarkers and guide personalized therapy selection. Our findings position miR-106b-5p as a previously unrecognized molecular bridge between cancer and doxorubicin-induced cardiotoxicity. The development of the AM106 antagomir represents a promising approach with potential clinical applicability in cardio-oncology, offering dual benefits: tumor control and cardioprotection. Coupling this innovation with AI-driven analysis of patient data may enable precision risk stratification, early intervention, and improved outcomes. miR-106b-5p thus emerges as a central therapeutic target and biomarker candidate for transforming the clinical management of cancer patients at risk for heart failure.
- 14 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10002
Open AccessmiR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology and cardiovascular disease. miR-106b-5p, a member of the miR-106b-25 cluster, has been widely studied for its oncogenic activity in various malignancies. However, its role as a direct molecular driver of anthracycline-induced cardiotoxicity has only recently been uncovered. This finding highlights new therapeutic possibilities at the intersection of oncology and cardiovascular medicine. This review outlines the dual role of miR-106b-5p as a key modulator in both tumor progression and chemotherapy-induced cardiac dysfunction. miR-106b-5p is upregulated in numerous cancers—including breast, prostate, lung, gastric, colorectal, hepatocellular, and esophageal—and promotes tumorigenesis via suppression of tumor suppressors such as PTEN, BTG3, p21, and SMAD7, leading to activation of oncogenic pathways like PI3K/AKT and TGF-β. Importantly, we present the first evidence that miR-106b-5p is significantly upregulated in the myocardium in response to doxorubicin treatment, where it drives left ventricular dysfunction by targeting PR55α, a key regulator of PP2A activity. This pathway results in cytoplasmic HDAC4 accumulation, aberrant activation of the YY1 transcription factor, and upregulation of sST2, a biomarker linked to adverse cardiac remodeling and poor prognosis. In response, we developed AM106, a novel locked nucleic acid antagomir that silences miR-106 b-5p. Preclinical studies demonstrate that AM106 restores PR55α/PP2A activity, reduces sST2 expression, and prevents structural and functional cardiac damage without compromising anti-tumor efficacy. In parallel, artificial intelligence (AI) tools could be leveraged in the future—based on established AI applications in miRNA cancer research—to accelerate the identification of miR-106b-5p-related biomarkers and guide personalized therapy selection. Our findings position miR-106b-5p as a previously unrecognized molecular bridge between cancer and doxorubicin-induced cardiotoxicity. The development of the AM106 antagomir represents a promising approach with potential clinical applicability in cardio-oncology, offering dual benefits: tumor control and cardioprotection. Coupling this innovation with AI-driven analysis of patient data may enable precision risk stratification, early intervention, and improved outcomes. miR-106b-5p thus emerges as a central therapeutic target and biomarker candidate for transforming the clinical management of cancer patients at risk for heart failure.
- Open Access
- 15 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
Background: The causal relationship between the activation of nuclear factor erythroid 2-related factor 2 (NRF2) and the preservation of SERCA2a function in mitigating myocardial ischemia–reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. This study aims to unravel how NRF2 directly or indirectly influences SERCA2a function and its regulators, phospholamban (PLN) and Dwarf Open Reading Frame (DWORF), by testing the pharmacological repositioning of AEOL-10150 (AEOL) in the context of mI/R injury. Methods: C57BL6/J, Nrf2 knockout ( Nrf2 −/− ), and wild-type ( Nrf2 + / + ) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. Results: In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2 −/− mice and in Nrf2 / Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Conclusions: Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- 15 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
Open AccessAEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
Background: The causal relationship between the activation of nuclear factor erythroid 2-related factor 2 (NRF2) and the preservation of SERCA2a function in mitigating myocardial ischemia–reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. This study aims to unravel how NRF2 directly or indirectly influences SERCA2a function and its regulators, phospholamban (PLN) and Dwarf Open Reading Frame (DWORF), by testing the pharmacological repositioning of AEOL-10150 (AEOL) in the context of mI/R injury. Methods: C57BL6/J, Nrf2 knockout ( Nrf2 −/− ), and wild-type ( Nrf2 + / + ) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. Results: In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2 −/− mice and in Nrf2 / Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Conclusions: Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- Open Access
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1607362
Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
Heart failure with reduced ejection fraction (HFrEF) remains a significant global health concern, characterized by high rates of morbidity, mortality, and frequent hospitalizations. Despite substantial progress in medical therapies over the past decades, the clinical course of HFrEF is often progressive, necessitating continuous research into novel and refined therapeutic strategies to improve patient outcomes. The management of HFrEF is a dynamic field, with clinical practice guidelines undergoing regular updates to incorporate the latest evidence and emerging treatment approaches. This constant evolution underscores the importance of ongoing investigation and the need for healthcare professionals to remain informed about the newest advancements in this area. The research topic "Advanced Therapeutic Strategies and Safety Profiles in Heart Failure with Reduced Ejection Fraction," published in Frontiers in Pharmacology, serves as a valuable platform for the dissemination of cutting-edge research focused on enhancing the treatment and safety profiles for individuals living with HFrEF. This topic encompasses a wide range of investigations, including the application of artificial intelligence and machine learning for predicting therapeutic outcomes, detailed evaluations of drug efficacy and safety across diverse patient populations, comparative studies of different treatment strategies, clinical trials exploring novel pharmacological agents, and the integration of advanced diagnostic tools to personalize treatment responses. This editorial aims to critically analyze and contextualize three specific studies recently published within this research topic, integrating their findings with the current understanding of HFrEF management up to the year 2025.By examining these recent contributions, this editorial seeks to provide an expert perspective on their significance and potential impact on the evolving landscape of HFrEF therapy.The cornerstone of contemporary HFrEF management lies in the implementation of guideline-directed medical therapy (GDMT), which has demonstrably improved survival and reduced hospitalizations (Heidenreich et al., 2022;Carrizales-Sepúlveda et al., 2024;Beghini et al., 2025). This foundational approach is built upon the synergistic effects of four main classes of medications: Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), which are often preferred as first-line renin-angiotensin system inhibitors due to their superior efficacy compared to ACE inhibitors or angiotensin receptor blockers; betablockers, which play a crucial role in mitigating the detrimental effects of the sympathetic nervous system; mineralocorticoid receptor antagonists (MRAs), which help to counteract the effects of aldosterone; and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is), which have emerged as a transformative therapy demonstrating significant benefits in reducing heart failure hospitalizations and cardiovascular mortality across a broad range of patients with and without diabetes. Current guidelines increasingly emphasize the importance of initiating and rapidly up-titrating these four foundational therapies to their maximally tolerated doses within the first few months following diagnosis to achieve optimal clinical outcomes. Major guideline updates, such as the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the 2023 ESC Focused Update of the 2021 ESC Guidelines, have further refined the recommendations for HFrEF management (Heidenreich et al., 2022). Notably, these updates highlight the expanded role of SGLT2 inhibitors across the entire spectrum of left ventricular ejection fraction, signifying a significant shift in the therapeutic paradigm (Carrizales-Sepúlveda et al., 2024).Beyond these foundational therapies, other emerging strategies and considerations have gained prominence in the management of HFrEF up to 2025 (Beghini et al., 2025).Vericiguat, an oral soluble guanylate cyclase stimulator, is recommended for consideration in patients with worsening HFrEF despite optimal GDMT, based on the findings of the VICTORIA trial (PW et al., 2020). Intravenous iron supplementation is increasingly recognized for its benefits in symptomatic patients with HFrEF and iron deficiency, improving symptoms and quality of life and potentially reducing heart failure hospitalizations (Beghini et al., 2025). Furthermore, the integration of palliative care into the management of advanced heart failure is gaining increasing recognition as a crucial component for improving patient quality of life and addressing their individual goals of care (Carrizales-Sepúlveda et al., 2024). The 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction further reinforces the central role of the "four pillars" of GDMT, emphasizing the preferred use of ARNIs as the initial renin-angiotensin system inhibitor in eligible patients. In this updated pathway, ACE inhibitors and angiotensin receptor blockers are primarily considered in patients who have contraindications, intolerance, or limited access to ARNIs (Maddox et al., 2024).Within the Frontiers in pharmacology, three recent studies offer valuable insights into advanced therapeutic strategies and safety profiles in HFrEF. Study 1: Vericiguat in Post-Acute Heart Failure (Li et al., 2025). This retrospective, singlecenter study sought to evaluate the safety and efficacy of vericiguat in 100 patients hospitalized for acute heart failure (HF) who were subsequently followed up as outpatients for a median of 68 days (Li et al., 2025). These patients, representing a diverse group with HFrEF, HFmrEF, and HFpEF, were compared to a propensity score-matched external control group of 75 patients who received standard HF therapy without vericiguat during the same period. The study's design, including patients with various heart failure subtypes, broadens the scope of its findings beyond just...
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1607362
Open AccessEditorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
Heart failure with reduced ejection fraction (HFrEF) remains a significant global health concern, characterized by high rates of morbidity, mortality, and frequent hospitalizations. Despite substantial progress in medical therapies over the past decades, the clinical course of HFrEF is often progressive, necessitating continuous research into novel and refined therapeutic strategies to improve patient outcomes. The management of HFrEF is a dynamic field, with clinical practice guidelines undergoing regular updates to incorporate the latest evidence and emerging treatment approaches. This constant evolution underscores the importance of ongoing investigation and the need for healthcare professionals to remain informed about the newest advancements in this area. The research topic "Advanced Therapeutic Strategies and Safety Profiles in Heart Failure with Reduced Ejection Fraction," published in Frontiers in Pharmacology, serves as a valuable platform for the dissemination of cutting-edge research focused on enhancing the treatment and safety profiles for individuals living with HFrEF. This topic encompasses a wide range of investigations, including the application of artificial intelligence and machine learning for predicting therapeutic outcomes, detailed evaluations of drug efficacy and safety across diverse patient populations, comparative studies of different treatment strategies, clinical trials exploring novel pharmacological agents, and the integration of advanced diagnostic tools to personalize treatment responses. This editorial aims to critically analyze and contextualize three specific studies recently published within this research topic, integrating their findings with the current understanding of HFrEF management up to the year 2025.By examining these recent contributions, this editorial seeks to provide an expert perspective on their significance and potential impact on the evolving landscape of HFrEF therapy.The cornerstone of contemporary HFrEF management lies in the implementation of guideline-directed medical therapy (GDMT), which has demonstrably improved survival and reduced hospitalizations (Heidenreich et al., 2022;Carrizales-Sepúlveda et al., 2024;Beghini et al., 2025). This foundational approach is built upon the synergistic effects of four main classes of medications: Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), which are often preferred as first-line renin-angiotensin system inhibitors due to their superior efficacy compared to ACE inhibitors or angiotensin receptor blockers; betablockers, which play a crucial role in mitigating the detrimental effects of the sympathetic nervous system; mineralocorticoid receptor antagonists (MRAs), which help to counteract the effects of aldosterone; and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is), which have emerged as a transformative therapy demonstrating significant benefits in reducing heart failure hospitalizations and cardiovascular mortality across a broad range of patients with and without diabetes. Current guidelines increasingly emphasize the importance of initiating and rapidly up-titrating these four foundational therapies to their maximally tolerated doses within the first few months following diagnosis to achieve optimal clinical outcomes. Major guideline updates, such as the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the 2023 ESC Focused Update of the 2021 ESC Guidelines, have further refined the recommendations for HFrEF management (Heidenreich et al., 2022). Notably, these updates highlight the expanded role of SGLT2 inhibitors across the entire spectrum of left ventricular ejection fraction, signifying a significant shift in the therapeutic paradigm (Carrizales-Sepúlveda et al., 2024).Beyond these foundational therapies, other emerging strategies and considerations have gained prominence in the management of HFrEF up to 2025 (Beghini et al., 2025).Vericiguat, an oral soluble guanylate cyclase stimulator, is recommended for consideration in patients with worsening HFrEF despite optimal GDMT, based on the findings of the VICTORIA trial (PW et al., 2020). Intravenous iron supplementation is increasingly recognized for its benefits in symptomatic patients with HFrEF and iron deficiency, improving symptoms and quality of life and potentially reducing heart failure hospitalizations (Beghini et al., 2025). Furthermore, the integration of palliative care into the management of advanced heart failure is gaining increasing recognition as a crucial component for improving patient quality of life and addressing their individual goals of care (Carrizales-Sepúlveda et al., 2024). The 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction further reinforces the central role of the "four pillars" of GDMT, emphasizing the preferred use of ARNIs as the initial renin-angiotensin system inhibitor in eligible patients. In this updated pathway, ACE inhibitors and angiotensin receptor blockers are primarily considered in patients who have contraindications, intolerance, or limited access to ARNIs (Maddox et al., 2024).Within the Frontiers in pharmacology, three recent studies offer valuable insights into advanced therapeutic strategies and safety profiles in HFrEF. Study 1: Vericiguat in Post-Acute Heart Failure (Li et al., 2025). This retrospective, singlecenter study sought to evaluate the safety and efficacy of vericiguat in 100 patients hospitalized for acute heart failure (HF) who were subsequently followed up as outpatients for a median of 68 days (Li et al., 2025). These patients, representing a diverse group with HFrEF, HFmrEF, and HFpEF, were compared to a propensity score-matched external control group of 75 patients who received standard HF therapy without vericiguat during the same period. The study's design, including patients with various heart failure subtypes, broadens the scope of its findings beyond just...
- Open Access
- 15 May 2024
- Published by Springer Nature in Research Square
AEOL-Induced NRF2 Activation and DWORF Overexpression Mitigate Myocardial I/R Injury
The causal relationship between the activation of NRF2 and the preservation of SERCA2a function in mitigating myocardial ischemia-reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. The aim of this study was to characterize this relationship by testing the pharmacological repositioning of AEOL-10150 (AEOL) as a novel NRF2 activator. C57BL6/J, Nrf2 knockout (Nrf2−/−), and wild-type (Nrf2+/+) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2−/− mice and in Nrf2/Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- 15 May 2024
- Published by Springer Nature in Research Square
Open AccessAEOL-Induced NRF2 Activation and DWORF Overexpression Mitigate Myocardial I/R Injury
The causal relationship between the activation of NRF2 and the preservation of SERCA2a function in mitigating myocardial ischemia-reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. The aim of this study was to characterize this relationship by testing the pharmacological repositioning of AEOL-10150 (AEOL) as a novel NRF2 activator. C57BL6/J, Nrf2 knockout (Nrf2−/−), and wild-type (Nrf2+/+) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2−/− mice and in Nrf2/Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- Open Access
- 4 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 704-720
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
- 4 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 704-720
Open AccessSilencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
- Open Access
- 3 February 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (5) , 1321-1328
Critical warm ischemia time point for cardiac donation after circulatory death
- 3 February 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (5) , 1321-1328
Open AccessCritical warm ischemia time point for cardiac donation after circulatory death
- Open Access
- 16 February 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
Left ventricular remodeling following myocardial infarction (MI) is related to adverse outcome. It has been shown that an up-regulation of plasma soluble ST2 (sST2) levels are associated with lower pre-discharge left ventricular (LV) ejection fraction, adverse cardiovascular outcomes and mortality outcome after MI. The mechanisms involved in its modulation are unknown and there is not specific treatment capable of lowering plasma sST2 levels in acute-stage HF. We recently identified Yin-yang 1 (Yy1) as a transcription factor related to circulating soluble ST2 isoform (sST2) expression in infarcted myocardium. However, the underlying mechanisms involved in this process have not been thoroughly elucidated. This study aimed to evaluate the pathophysiological implication of miR-199a-5p in cardiac remodeling and the expression of the soluble ST2 isoform. Myocardial infarction (MI) was induced by permanent ligation of the left anterior coronary artery in C57BL6/J mice that randomly received antimiR199a therapy, antimiR-Ctrl or saline. A model of biomechanical stretching was also used to characterize the underlying mechanisms involved in the activation of Yy1/sST2 axis. Our results show that the significant upregulation of miR-199a-5p after myocardial infarction increases pathological cardiac hypertrophy by upregulating circulating soluble sST2 levels. AntimiR199a therapy up-regulates Sirt1 and inactivates the co-activator P300 protein, thus leading to Yy1 inhibition which decreases both expression and release of circulating sST2 by cardiomyocytes after myocardial infarction. Pharmacological inhibition of miR-199a rescues cardiac hypertrophy and heart failure in mice, offering a potential therapeutic approach for cardiac failure.
- 16 February 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Open AccessThe miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
Left ventricular remodeling following myocardial infarction (MI) is related to adverse outcome. It has been shown that an up-regulation of plasma soluble ST2 (sST2) levels are associated with lower pre-discharge left ventricular (LV) ejection fraction, adverse cardiovascular outcomes and mortality outcome after MI. The mechanisms involved in its modulation are unknown and there is not specific treatment capable of lowering plasma sST2 levels in acute-stage HF. We recently identified Yin-yang 1 (Yy1) as a transcription factor related to circulating soluble ST2 isoform (sST2) expression in infarcted myocardium. However, the underlying mechanisms involved in this process have not been thoroughly elucidated. This study aimed to evaluate the pathophysiological implication of miR-199a-5p in cardiac remodeling and the expression of the soluble ST2 isoform. Myocardial infarction (MI) was induced by permanent ligation of the left anterior coronary artery in C57BL6/J mice that randomly received antimiR199a therapy, antimiR-Ctrl or saline. A model of biomechanical stretching was also used to characterize the underlying mechanisms involved in the activation of Yy1/sST2 axis. Our results show that the significant upregulation of miR-199a-5p after myocardial infarction increases pathological cardiac hypertrophy by upregulating circulating soluble sST2 levels. AntimiR199a therapy up-regulates Sirt1 and inactivates the co-activator P300 protein, thus leading to Yy1 inhibition which decreases both expression and release of circulating sST2 by cardiomyocytes after myocardial infarction. Pharmacological inhibition of miR-199a rescues cardiac hypertrophy and heart failure in mice, offering a potential therapeutic approach for cardiac failure.
- Open Access
- 9 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1
Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 9 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1
Open AccessAuthor Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
An amendment to this paper has been published and can be accessed via a link at the top of the paper.